Jeff Yass’s Proshares UltraPro NASDAQ Biotechnology UBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-33,955
| Closed | -$1.11M | – | 11282 |
|
|
2019
Q4 | $1.11M | Buy |
+33,955
| New | +$903K | ﹤0.01% | 5323 |
|
|
2019
Q3 | – | Sell |
-15,074
| Closed | -$391K | – | 11180 |
|
|
2019
Q2 | $391K | Buy |
+15,074
| New | +$372K | ﹤0.01% | 7785 |
|
|
2019
Q1 | – | Sell |
-40,030
| Closed | -$1.14M | – | 10344 |
|
|
2018
Q4 | $801K | Buy |
+40,030
| New | +$1.13M | ﹤0.01% | 5110 |
|
|
2018
Q3 | – | Sell |
-23,744
| Closed | -$790K | – | 10695 |
|
|
2018
Q2 | $790K | Buy |
23,744
+9,331
| +65% | +$291K | ﹤0.01% | 5855 |
|
|
2018
Q1 | $459K | Sell |
14,413
-4,865
| -25% | -$179K | ﹤0.01% | 6809 |
|
|
2017
Q4 | $649K | Sell |
19,278
-11,031
| -36% | -$377K | ﹤0.01% | 6113 |
|
|
2017
Q3 | $1.17M | Buy |
30,309
+16,309
| +116% | +$568K | ﹤0.01% | 4997 |
|
|
2017
Q2 | $446K | Sell |
14,000
-9,346
| -40% | -$262K | ﹤0.01% | 6856 |
|
|
2017
Q1 | $646K | Buy |
+23,346
| New | +$615K | ﹤0.01% | 6011 |
|
|
2016
Q4 | – | Sell |
-19,693
| Closed | -$569K | – | 10425 |
|
|
2016
Q3 | $569K | Buy |
+19,693
| New | +$561K | ﹤0.01% | 5842 |
|
|
2016
Q2 | – | Sell |
-31,971
| Closed | -$810K | – | 9674 |
|
|
2016
Q1 | $757K | Buy |
31,971
+9,418
| +42% | +$260K | ﹤0.01% | 5644 |
|
|
2015
Q4 | $1.3M | Buy |
+22,553
| New | +$1.19M | ﹤0.01% | 4875 |
|
Other funds holding UBIO
Jeff Yass's UBIO Position: Q1 2020 in Review
Jeff Yass sold out of Proshares UltraPro NASDAQ Biotechnology (UBIO) in Q1 2020, closing a stake of 33,955 shares — an estimated $1.11M sold.
Jeff Yass first reported a position in UBIO in Q4 2015 and held it in 12 quarters. The position peaked at $1.3M in Q4 2015. 1 fund tracked by Wall St. Rank holds UBIO as of Q1 2020.
- Jeff Yass reported no remaining Proshares UltraPro NASDAQ Biotechnology position as of Q1 2020 after selling out during the quarter.
- Jeff Yass sold 33,955 Proshares UltraPro NASDAQ Biotechnology shares in Q1 2020, an estimated $1.11M.
- Jeff Yass first reported a position in Proshares UltraPro NASDAQ Biotechnology in Q4 2015 and held it in 12 quarters.
- Jeff Yass's Proshares UltraPro NASDAQ Biotechnology position peaked at $1.3M in Q4 2015.
- 1 fund tracked by Wall St. Rank held Proshares UltraPro NASDAQ Biotechnology as of Q1 2020.
Based on Susquehanna International Group's 13F filing for Q1 2020, filed 15 May 2020.